BIGBEAR Pharmaceutical announces the approval of Binimetinib and Encorafenib in Laos

Binimetinib is an ATP non-competitive, reversible inhibitor that inhibits the kinase activity of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2. MEK protein is an upstream regulator of the extracellular signal-related kinase (ERK) pathway, which promotes cell proliferation. In melanoma and other cancers, this pathway is often activated by mutated forms of BRAF that activate MEK. Binimetinib inhibits the activation of MEK by BRAF and inhibits MEK kinase activity.

Encorafenib is a small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway. This pathway occurs in many different cancers, including melanoma and colorectal cancer.

Encorafenib is used in combination with binimetinib to treat patients with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma.